ERBB2 and neoplasm: Compared with consistently good performances on both the study cohort and the external validation cohort in HER2+ subtype, it is also reasonable to suspect that the TNBC cohort may harbor more heterogeneous and complex tumor micro-environments than the HER2+ subtype.